Compare · AVTR vs NAUT
AVTR vs NAUT
Side-by-side comparison of Avantor Inc. (AVTR) and Nautilus Biotechnology Inc. (NAUT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and NAUT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $6.62B, about 22.3x NAUT ($296.1M).
- AVTR has been more active in the news (3 items in the past 4 weeks vs 2 for NAUT).
- AVTR has more recent analyst coverage (25 ratings vs 7 for NAUT).
- Company
- Avantor Inc.
- Nautilus Biotechnology Inc.
- Price
- $9.69+5.73%
- $2.32-3.13%
- Market cap
- $6.62B
- $296.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 3
- 2
- Recent ratings
- 25
- 7
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Nautilus Biotechnology Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.
Latest AVTR
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Murthy Mala was granted 25,270 shares, increasing direct ownership by 57% to 69,479 units (SEC Form 4)
- Director Lucier Gregory T was granted 25,270 shares and bought $83,200 worth of shares (10,000 units at $8.32), increasing direct ownership by 289% to 34,006 units (SEC Form 4)
- Director Dingemans Simon was granted 25,270 shares, increasing direct ownership by 406% to 31,495 units (SEC Form 4)
- Director Massaro Joseph R was granted 25,270 shares, increasing direct ownership by 48% to 77,408 units (SEC Form 4)
- Director Makin Louise was granted 25,270 shares, increasing direct ownership by 116% to 47,140 units (SEC Form 4)
Latest NAUT
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- Large owner Ah Equity Partners Bio Ii, L.L.C. sold $11,750,000 worth of shares (5,000,000 units at $2.35) (SEC Form 4)
- SEC Form DEFA14A filed by Nautilus Biotechnology Inc.
- SEC Form DEF 14A filed by Nautilus Biotechnology Inc.
- SEC Form 10-Q filed by Nautilus Biotechnology Inc.
- Nautilus Biotechnology Reports First Quarter 2026 Financial Results
- Nautilus Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
- Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
- Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform